Dolasetron

332 interactions 1 explained in plain English 421 cited references
Also sold as: Anzemet Anzemet®
About Dolasetron

Dolasetron is used to prevent nausea and vomiting caused by cancer chemotherapy. Dolasetron is in a class of medications called serotonin 5-HT3 receptor antagonists. It works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting. Read the full Dolasetron drug information page →

Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Piperaquine Phenelzine Saquinavir Pimozide Mesoridazine Sparfloxacin
16 Contraindicated 314 Major 1 Moderate 1 Minor
All (332) Contraindicated (16) Major (314) Moderate (1) Minor (1)

Major

Dolasetron Pasireotide Signifor Increased risk of QT prolongation Details Dolasetron Pazopanib Votrient An increased risk of QT interval prolongation Details Dolasetron Pentamidine NebuPent An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dolasetron Pentazocine Increased risk of serotonin syndrome Details Dolasetron Phenobarbital Fidoquel An increased risk of QT interval prolongation Details Dolasetron Pimavanserin Nuplazid An increased risk of QT interval prolongation Details Dolasetron Pirmenol Cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dolasetron Pitolisant Wakix Increased risk of QT interval prolongation Details Dolasetron Ponesimod Ponvory An increased risk of QT interval prolongation Details Dolasetron Posaconazole Noxafil An increased risk of QT interval prolongation Details Dolasetron Prajmaline Cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dolasetron Primidone Mysoline An increased risk of QT interval prolongation Details Dolasetron Probucol An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dolasetron Procainamide Procan® Cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dolasetron Procarbazine Increased risk of serotonin syndrome Details Dolasetron Prochlorperazine Cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dolasetron Promethazine Phenadoz An increased risk of QT interval prolongation Details Dolasetron Propafenone Rythmol An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dolasetron Protriptyline Increased risk of serotonin syndrome and QT-interval prolongation Details Dolasetron Quetiapine Seroquel An increased risk of QT interval prolongation Details Dolasetron Quinidine Cardioquin® Cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dolasetron Quinine An increased risk of QT interval prolongation Details Dolasetron Quizartinib Vanflyta An increased risk of QT interval prolongation Details Dolasetron Ranolazine Aspruzyo An increased risk of QT interval prolongation Details Dolasetron Rasagiline Azilect Increased risk of serotonin syndrome Details Dolasetron Remifentanil Increased risk of serotonin syndrome Details Dolasetron Revumenib Revuforj An increased risk of QT interval prolongation Details Dolasetron Ribociclib Kisqali An increased risk of QT interval prolongation Details Dolasetron Rilpivirine Edurant An increased risk of QT interval prolongation and torsade de pointes Details Dolasetron Risperidone Perseris An increased risk of cardiotoxicity (QT prolongation, torsade de pointes, cardiac arrest) Details Dolasetron Rizatriptan Increased risk of serotonin syndrome Details Dolasetron Selegiline Anipryl Increased risk of serotonin syndrome Details Dolasetron Selpercatinib Retevmo Increased risk of QT interval prolongation Details Dolasetron Sematilide Cardiotoxicity (QT prolongation, torsade de pointes, cardiac arrest) Details Dolasetron Sertindole An increased risk of cardiotoxicity (QT prolongation, torsade de pointes, cardiac arrest) Details Dolasetron Sevoflurane Petrem Increased risk of QT interval prolongation Details Dolasetron Sibutramine Increased risk of serotonin syndrome Details Dolasetron Siponimod Mayzent An increased risk of QT interval prolongation Details Dolasetron Sodium Phosphate OsmoPrep An increased risk of QT interval prolongation Details Dolasetron Sodium Phosphate, Dibasic An increased risk of QT interval prolongation Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.